Ling Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ling Xue has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Qinghua Cao
Department of Pathology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
4 shared publicationsYuan Lin
Department of Pathology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
4 shared publicationsFang Liu
Cancer Center, Southern Medical University, Guangzhou 510315, China
3 shared publicationsLi Ding
Department of Pathology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
3 shared publicationsZiyin Ye
Department of Pathology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
3 shared publications- Bihui Huang
Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China
2 shared publications
Latest Publications
- 16 September 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt A) , 113108
Corrigendum to “Secretory Nogo-B regulates Th2 differentiation in the lung cancer microenvironment” [Int. Immunopharmacol. 140 (2024) 112763]
- 16 September 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt A) , 113108
Corrigendum to “Secretory Nogo-B regulates Th2 differentiation in the lung cancer microenvironment” [Int. Immunopharmacol. 140 (2024) 112763]
- 29 July 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 140, 112763
Secretory Nogo-B regulates Th2 differentiation in the lung cancer microenvironment
- 29 July 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 140, 112763
Secretory Nogo-B regulates Th2 differentiation in the lung cancer microenvironment
- Open Access
- 1 August 2021
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 10 (8) , 3864-3869
ALK-positive pulmonary adenocarcinoma with signet ring features (PASRF) and polygonal cell morphology simultaneously co-expressing TTF-1/p63/P40: a case report
ALK-positive pulmonary adenocarcinoma with signet ring features (PASRF) and polygonal cell morphology simultaneously co-expressing TTF-1/p63/P40: a case report Yang Tan, Xiaofang Lu, Yun Li, Dingzhun Liao, Wenlin Xie, Jian Song, Ling Xue, Junfeng Zhu
- 1 August 2021
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 10 (8) , 3864-3869
Open AccessALK-positive pulmonary adenocarcinoma with signet ring features (PASRF) and polygonal cell morphology simultaneously co-expressing TTF-1/p63/P40: a case report
ALK-positive pulmonary adenocarcinoma with signet ring features (PASRF) and polygonal cell morphology simultaneously co-expressing TTF-1/p63/P40: a case report Yang Tan, Xiaofang Lu, Yun Li, Dingzhun Liao, Wenlin Xie, Jian Song, Ling Xue, Junfeng Zhu
- Open Access
- 28 December 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (2) , 2107-2116
DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway
Deleted in liver cancer 2 (DLC2) is a tumor suppressor, associated with various types of cancer. The aim of the present study was to analyze the expression of DLC2 in breast cancer, its clinical significance and its effect on breast cancer cell behavior. The expression of DLC2 was evaluated by immunohistochemistry in 131 cases of breast cancer. Associations among DLC2 expression and clinicopathological features were analyzed, and its effects on proliferation, motility, migration and invasion in DLC2‑knockdown breast cancer cell lines were observed. The results indicated that DLC2 was expressed in 42.75% of breast cancer cases (56/131) and in 79.39% of adjacent normal tissues (104/131). Lower expression of DLC2 in breast cancer was associated with tumor differentiation (P<0.001), lymph node metastasis (P<0.001) and poor prognosis (P<0.001). The silencing of the DLC2 gene in human breast cancer cell indicated an increased number of cells entering S phase, and increased abilities of clone formation, cell migration and invasion. Downregulated expression of DLC2 was associated with activated Ras homolog family member A and decreased Rac family small GTPase 1, cell division cycle 42 and Rho‑associated protein kinase‑2 expression levels, indicating that DLC2 may serve a regulatory function in breast cancer cell proliferation and invasion via the RhoGTPase pathway. The results of the present study suggested that DLC2 serves as a suppressor gene in the development of breast cancer and may be a prognostic marker for patients with breast cancer.
- 28 December 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (2) , 2107-2116
Open AccessDLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway
Deleted in liver cancer 2 (DLC2) is a tumor suppressor, associated with various types of cancer. The aim of the present study was to analyze the expression of DLC2 in breast cancer, its clinical significance and its effect on breast cancer cell behavior. The expression of DLC2 was evaluated by immunohistochemistry in 131 cases of breast cancer. Associations among DLC2 expression and clinicopathological features were analyzed, and its effects on proliferation, motility, migration and invasion in DLC2‑knockdown breast cancer cell lines were observed. The results indicated that DLC2 was expressed in 42.75% of breast cancer cases (56/131) and in 79.39% of adjacent normal tissues (104/131). Lower expression of DLC2 in breast cancer was associated with tumor differentiation (P<0.001), lymph node metastasis (P<0.001) and poor prognosis (P<0.001). The silencing of the DLC2 gene in human breast cancer cell indicated an increased number of cells entering S phase, and increased abilities of clone formation, cell migration and invasion. Downregulated expression of DLC2 was associated with activated Ras homolog family member A and decreased Rac family small GTPase 1, cell division cycle 42 and Rho‑associated protein kinase‑2 expression levels, indicating that DLC2 may serve a regulatory function in breast cancer cell proliferation and invasion via the RhoGTPase pathway. The results of the present study suggested that DLC2 serves as a suppressor gene in the development of breast cancer and may be a prognostic marker for patients with breast cancer.
- Open Access
- 23 January 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 94
Testes-specific protease 50 (TSP50) promotes invasion and metastasis by inducing EMT in gastric cancer
TSP50 (testes-specific protease 50) has been reported to be a candidate oncogene and is overexpressed in various cancers. Our previous study demonstrated that TSP50 protein is elevated in gastric cancer, and its high expression is associated with unfavorable prognosis and lymph node metastasis. However, the role of TSP50 in gastric cancer remains elusive. qRT-PCR, western blot were used to determine TSP50 expression in gastric cancer cell lines. Role of TSP50 in proliferation and invasion was examined by BrdU incorporation assay, cell count, wound healing and transwell assay. Immunohistochemistry and western blot were performed to identify the potential mechanisms involved. TSP50 was highly expressed in most of the gastric cancer cell lines at both mRNA and protein levels. Up-regulation of TSP50 in gastric cancer cells enhanced proliferation and invasiveness, whereas down-regulation of TSP50 by its specific shRNA decreased it. A negative correlation between TSP50 and E-Cadherin was found in gastric cancer tissues, and combination of them improves the prediction for prognosis and lymph node metastasis. Mechanistic studies revealed that overexpression of TSP50 increased the expression of epithelial-to-mesenchymal transition (EMT) markers including Vimentin, and Twist, and decreased the epithelial marker E-Cadherin. NF-κB signaling pathway is involved in the regulatory effects of TSP50 on EMT, migration and invasion in gastric cancer cells. TSP50 promotes the proliferation, migration and invasion of gastric cancer cells involving NF-κB dependent EMT activation. Targeting TSP50 may provide a novel therapeutic strategy for the management of gastric cancer.
- 23 January 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 94
Open AccessTestes-specific protease 50 (TSP50) promotes invasion and metastasis by inducing EMT in gastric cancer
TSP50 (testes-specific protease 50) has been reported to be a candidate oncogene and is overexpressed in various cancers. Our previous study demonstrated that TSP50 protein is elevated in gastric cancer, and its high expression is associated with unfavorable prognosis and lymph node metastasis. However, the role of TSP50 in gastric cancer remains elusive. qRT-PCR, western blot were used to determine TSP50 expression in gastric cancer cell lines. Role of TSP50 in proliferation and invasion was examined by BrdU incorporation assay, cell count, wound healing and transwell assay. Immunohistochemistry and western blot were performed to identify the potential mechanisms involved. TSP50 was highly expressed in most of the gastric cancer cell lines at both mRNA and protein levels. Up-regulation of TSP50 in gastric cancer cells enhanced proliferation and invasiveness, whereas down-regulation of TSP50 by its specific shRNA decreased it. A negative correlation between TSP50 and E-Cadherin was found in gastric cancer tissues, and combination of them improves the prediction for prognosis and lymph node metastasis. Mechanistic studies revealed that overexpression of TSP50 increased the expression of epithelial-to-mesenchymal transition (EMT) markers including Vimentin, and Twist, and decreased the epithelial marker E-Cadherin. NF-κB signaling pathway is involved in the regulatory effects of TSP50 on EMT, migration and invasion in gastric cancer cells. TSP50 promotes the proliferation, migration and invasion of gastric cancer cells involving NF-κB dependent EMT activation. Targeting TSP50 may provide a novel therapeutic strategy for the management of gastric cancer.
- 1 May 2017
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (5) , 570-573
Synchronous carcinosarcoma of the uterine cervix with adenoid basal carcinoma and cervical intraepithelial neoplasia III: A case report and literature review
- 1 May 2017
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (5) , 570-573
Synchronous carcinosarcoma of the uterine cervix with adenoid basal carcinoma and cervical intraepithelial neoplasia III: A case report and literature review
- Open Access
- 1 December 2015
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (49) , e2157
Granulomas as the Most Useful Histopathological Feature in Distinguishing between Crohn's Disease and Intestinal Tuberculosis in Endoscopic Biopsy Specimens
The incidence of Crohn's disease (CD) is increasing in Chinese populations in whom intestinal tuberculosis (ITB) is prevalent. This study aimed to identify differential diagnostic microscopic and endoscopic characteristics of CD from those of ITB. Patients with CD (N = 52) and patients with ITB (N = 16) diagnosed between 2010 and 2013 were identified. Specimens obtained via endoscopy were analyzed microscopically by a pathologist. The relationship between endoscopic appearance and histopathological features was analyzed. The χ2 test, Fisher's exact probability test, and the Mann-Whitney U test were used. Granulomas were present in 81.3% of ITB cases and in 67.3% of CD cases (P = 0.36). Granulomas in ITB cases were denser than those in CD cases (mean 5.29 ± 4.30 vs. 2.46 ± 3.50 granulomas per 10 low power fields; each low power field = 3.80 mm2; P = 0.005). Granulomas in ITB cases were larger (mean widest diameter, 508 ± 314 μm; range, 100–1100 μm) than those in CD cases (mean widest diameter, 253 ± 197 μm; range, 50–800 μm). Basal plasmacytosis was more common in CD cases than in ITB cases (77.0% vs. 37.5%, P = 0.000). Endoscopy findings such as longitudinal ulcer, aphthous ulcer, and cobblestone appearance were only seen in CD cases (34.6%, 21.2%, and 23.1%, respectively). Granulomas were detected in the majority of cases with longitudinal ulcers (88.9%). Basal plasmacytosis was exclusively detected in cases with longitudinal ulcer and a cobblestone appearance. Characteristics of granulomas maybe the most important distinguishing features between CD and ITB. However, the histopathological characteristics of both diseases may overlap on endoscopic biopsy specimens. An accurate diagnosis should be made that considers clinical, endoscopic features, and pathologic findings.
- 1 December 2015
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (49) , e2157
Open AccessGranulomas as the Most Useful Histopathological Feature in Distinguishing between Crohn's Disease and Intestinal Tuberculosis in Endoscopic Biopsy Specimens
The incidence of Crohn's disease (CD) is increasing in Chinese populations in whom intestinal tuberculosis (ITB) is prevalent. This study aimed to identify differential diagnostic microscopic and endoscopic characteristics of CD from those of ITB. Patients with CD (N = 52) and patients with ITB (N = 16) diagnosed between 2010 and 2013 were identified. Specimens obtained via endoscopy were analyzed microscopically by a pathologist. The relationship between endoscopic appearance and histopathological features was analyzed. The χ2 test, Fisher's exact probability test, and the Mann-Whitney U test were used. Granulomas were present in 81.3% of ITB cases and in 67.3% of CD cases (P = 0.36). Granulomas in ITB cases were denser than those in CD cases (mean 5.29 ± 4.30 vs. 2.46 ± 3.50 granulomas per 10 low power fields; each low power field = 3.80 mm2; P = 0.005). Granulomas in ITB cases were larger (mean widest diameter, 508 ± 314 μm; range, 100–1100 μm) than those in CD cases (mean widest diameter, 253 ± 197 μm; range, 50–800 μm). Basal plasmacytosis was more common in CD cases than in ITB cases (77.0% vs. 37.5%, P = 0.000). Endoscopy findings such as longitudinal ulcer, aphthous ulcer, and cobblestone appearance were only seen in CD cases (34.6%, 21.2%, and 23.1%, respectively). Granulomas were detected in the majority of cases with longitudinal ulcers (88.9%). Basal plasmacytosis was exclusively detected in cases with longitudinal ulcer and a cobblestone appearance. Characteristics of granulomas maybe the most important distinguishing features between CD and ITB. However, the histopathological characteristics of both diseases may overlap on endoscopic biopsy specimens. An accurate diagnosis should be made that considers clinical, endoscopic features, and pathologic findings.
- Open Access
- 7 August 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-8
Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma
Golgi phosphoprotein 3 (GOLPH3) has been identified as an oncoprotein in various human cancers; however, its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. We examined GOLPH3 expression levels and relationship with survival in patients with PDAC to establish the significance of GOLPH3 in the development and progression of PDAC. Real-time qPCR and Western blotting were performed to analyze the expression levels of GOLPH3 mRNA and protein in paired PDAC tumor and adjacent non-tumor tissues. Immunohistochemistry was used to analyze the expression levels of GOLPH3 protein in paraffin-embedded tissues from 109 cases of PDAC. Univariate and multivariate analyses were performed to identify correlations between the immunohistochemical data for GOLPH3 expression and the clinicopathologic characteristics in PDAC. Expression levels of GOLPH3 mRNA and protein were upregulated in PDAC lesions compared to paired adjacent noncancerous tissues. Expression of GOLPH3 was significantly correlated with clinical stage (P = 0.006), T classification (P = 0.021), N classification (P = 0.049) and liver metastasis (P = 0.035). Patients with high GOLPH3 expression had shorter overall survival times compared to those with low GOLPH3 expression (P = 0.007). Multivariate analysis revealed that GOLPH3 overexpression was an independent prognostic factor in PDAC. Our findings suggest that GOLPH3 expression status may be a potential prognostic biomarker and therapeutic target in PCAC.
- 7 August 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-8
Open AccessOverexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma
Golgi phosphoprotein 3 (GOLPH3) has been identified as an oncoprotein in various human cancers; however, its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. We examined GOLPH3 expression levels and relationship with survival in patients with PDAC to establish the significance of GOLPH3 in the development and progression of PDAC. Real-time qPCR and Western blotting were performed to analyze the expression levels of GOLPH3 mRNA and protein in paired PDAC tumor and adjacent non-tumor tissues. Immunohistochemistry was used to analyze the expression levels of GOLPH3 protein in paraffin-embedded tissues from 109 cases of PDAC. Univariate and multivariate analyses were performed to identify correlations between the immunohistochemical data for GOLPH3 expression and the clinicopathologic characteristics in PDAC. Expression levels of GOLPH3 mRNA and protein were upregulated in PDAC lesions compared to paired adjacent noncancerous tissues. Expression of GOLPH3 was significantly correlated with clinical stage (P = 0.006), T classification (P = 0.021), N classification (P = 0.049) and liver metastasis (P = 0.035). Patients with high GOLPH3 expression had shorter overall survival times compared to those with low GOLPH3 expression (P = 0.007). Multivariate analysis revealed that GOLPH3 overexpression was an independent prognostic factor in PDAC. Our findings suggest that GOLPH3 expression status may be a potential prognostic biomarker and therapeutic target in PCAC.
- Open Access
- 30 March 2014
- Published by Hindawi Limited in Gastroenterology Research and Practice
- Vol. 2014, 1-7
Overexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer
Purpose. To investigate the expression of TSP50 protein in human gastric cancers and its correlation with clinical/prognostic significance.Methods. Immunohistochemistry (IHC) analysis of TSP50 was performed on a tissue microarray (TMA) containing 334 primary gastric cancers. Western blot was carried out to confirm the expression of TSP50 in gastric cancers.Results. IHC analysis revealed high expression of TSP50 in 57.2% human gastric cancer samples (191 out of 334). However, it was poorly expressed in all of the 20 adjacent nontumor tissues. This was confirmed by western blot, which showed significantly higher levels of TSP50 expression in gastric cancer tissues than adjacent nontumor tissues. A significant association was found between high levels of TSP50 and clinicopathological characteristics including junior age at surgery (), later TNM stage (), and present lymph node metastases (). The survival of gastric cancer patients with high expression of TSP50 was significantly shorter than that of the patients with low levels of TSP50 (). Multivariate Cox regression analysis indicated that TSP50 overexpression was an independent prognostic factor for gastric cancer patients ().Conclusions. Our data demonstrate that elevated TSP50 protein expression could be a potential predictor of poor prognosis in gastric cancer patients.- 30 March 2014
- Published by Hindawi Limited in Gastroenterology Research and Practice
- Vol. 2014, 1-7
Open AccessOverexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer
Purpose. To investigate the expression of TSP50 protein in human gastric cancers and its correlation with clinical/prognostic significance.Methods. Immunohistochemistry (IHC) analysis of TSP50 was performed on a tissue microarray (TMA) containing 334 primary gastric cancers. Western blot was carried out to confirm the expression of TSP50 in gastric cancers.Results. IHC analysis revealed high expression of TSP50 in 57.2% human gastric cancer samples (191 out of 334). However, it was poorly expressed in all of the 20 adjacent nontumor tissues. This was confirmed by western blot, which showed significantly higher levels of TSP50 expression in gastric cancer tissues than adjacent nontumor tissues. A significant association was found between high levels of TSP50 and clinicopathological characteristics including junior age at surgery (), later TNM stage (), and present lymph node metastases (). The survival of gastric cancer patients with high expression of TSP50 was significantly shorter than that of the patients with low levels of TSP50 (). Multivariate Cox regression analysis indicated that TSP50 overexpression was an independent prognostic factor for gastric cancer patients ().Conclusions. Our data demonstrate that elevated TSP50 protein expression could be a potential predictor of poor prognosis in gastric cancer patients. - 1 January 2014
- Published by Elsevier in Pathology - Research and Practice
- Vol. 210 (1) , 55-58
Cardiac myxoma with glandular elements: A clinicopathological and immunohistochemical study of five new cases with an emphasis on differential diagnosis
- 1 January 2014
- Published by Elsevier in Pathology - Research and Practice
- Vol. 210 (1) , 55-58
Cardiac myxoma with glandular elements: A clinicopathological and immunohistochemical study of five new cases with an emphasis on differential diagnosis